DEF: CAMP4 Therapeutics Sets Date for 2025 Annual Stockholders Meeting

CAMP4 Therapeutics Corporation will hold its 2025 annual meeting of stockholders virtually on June 11, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Summary

• CAMP4 Therapeutics Corporation will hold its 2025 Annual Meeting of Stockholders on June 11, 2025, at 11:00 a.m.
• Eastern Daylight Time, in a virtual meeting format.
• The meeting will include the election of James Boylan, Amir Nashat, Andrew J.
• Schwab, and Douglas Williams as Class I directors for a three-year term expiring in 2028.
• Stockholders will also vote to ratify the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The record date for determining stockholders eligible to vote is April 14, 2025.
• As of the record date, 20,161,073 shares of common stock were outstanding.
• The company is providing proxy materials online and commenced sending notices to stockholders on or about April 30, 2025.
• The Board of Directors recommends voting FOR the election of the director nominees and FOR the ratification of Ernst & Young LLP.

Sentiment

Score: 7

Explanation: The document is neutral in tone, primarily conveying information about the upcoming annual meeting and corporate governance matters. There are no overtly positive or negative statements, resulting in a moderately positive sentiment score.

Positives

• The company is utilizing a virtual meeting format, which can increase accessibility for stockholders.
• Stockholders have multiple options for voting, including online, by phone, and by mail.
• The Board of Directors is actively engaged in risk oversight through its committees.
• The company has adopted a Code of Business Conduct and Ethics and an insider trading policy.
• The company has a clawback policy in place for incentive compensation.

Negatives

• Ingo Chakravarty, a current Class I director, will not be standing for re-election, reducing the board size to eleven members.
• Codiak BioSciences, where Douglas Williams served as CEO, filed for bankruptcy in March 2023.
• Pear Therapeutics, where Yuri Maricich served as Chief Medical Officer, filed for bankruptcy protection in April 2023.

Risks

• The company is an emerging growth company and has reduced public company reporting requirements.
• The company's certificate of incorporation allows directors to be removed only for cause with a 75% vote, potentially entrenching management.
• The limitation of liability and indemnification provisions in the company's governing documents may discourage lawsuits against directors.
• The company's related person transaction policy relies on audit committee review, which may not eliminate all potential conflicts of interest.

Future Outlook

The document outlines the agenda and procedures for the upcoming annual meeting, focusing on the election of directors and ratification of the accounting firm, but does not provide specific forward-looking statements about the company's financial performance or strategic direction.

Management Comments

• Josh Mandel-Brehm, Chief Executive Officer and Director, expresses gratitude for stockholders' continued support.
• The Board of Directors recommends voting FOR the election of director nominees and FOR the ratification of Ernst & Young LLP.

Industry Context

The document reflects standard corporate governance practices for publicly traded companies, including the solicitation of proxies, election of directors, and appointment of auditors. The virtual meeting format aligns with a growing trend toward increased accessibility and cost-effectiveness in shareholder meetings.

Comparison to Industry Standards

• The board structure, with classified terms and a mix of independent and non-independent directors, is common among publicly traded companies.
• The use of a virtual annual meeting is increasingly prevalent, mirroring practices adopted by companies like Zoom and Microsoft to enhance accessibility.
• The director compensation policy, including cash retainers and equity grants, is generally in line with industry benchmarks for similarly sized companies.
• The company's clawback policy aligns with the requirements of the Dodd-Frank Act and is a standard practice for public companies.
• The related person transaction policy is consistent with SEC regulations and aims to ensure transparency and fairness in dealings with related parties.

Management Changes

Corporate Governance

Related Party Transactions

• In October 2024, we completed our initial public offering, pursuant to which we issued and sold an aggregate of 6,820,000 shares of our common stock at a price per share of $11.00.
• In November 2024, pursuant to the partial exercise by the underwriters of their option to purchase additional shares, we issued an additional 643,762 shares of our common stock.
• The Mandel-Brehm Promissory Note, including $619,678 of principal and interest owed to the Company, was forgiven in June 2024.
• In January 2025, the Company paid Mr. Mandel-Brehm a cash bonus of $501,716 to assist him with taxes incurred in connection with such forgiveness.
• The Gold Promissory Note, including $140,139 of principal and interest owed to the Company, was forgiven in June 2024.
• In January 2025, the Company paid Ms. Gold a cash bonus of $101,480 to assist her with taxes incurred in connection with such forgiveness.
• The Bumcrot Promissory Note, including $140,129 of principal and interest owed to the Company, was forgiven in June 2024.
• In January 2025, the Company paid Dr. Bumcrot a cash bonus of $101,473 to assist him with taxes incurred in connection with such forgiveness.

Stakeholder Impact

• Shareholders have the opportunity to vote on key corporate governance matters.
• Employees are subject to the company's Code of Business Conduct and Ethics and insider trading policy.
• The appointment of an independent accounting firm ensures the reliability of financial reporting for all stakeholders.
• The company's related person transaction policy aims to protect the interests of all stakeholders.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold the Annual Meeting on June 11, 2025.
• The Board will consider the results of the votes on the proposals.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Board of Directors, Director Election, Ernst & Young, Stockholders, CAMP4 Therapeutics, Corporate Governance